













The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals, and more. Also pictured are the range of multipurpose prevention technologies (MPTs) in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

PRE-CLINICAL			PHASE I		PHASE II		PHASE III		IMPLEMENTATION		Delivery System		Active Drug		
 TAF	CONRAD	 MAVR TFV	Nigerian Institute for Medical Research		 FTC/TAF	Gilead <i>Event-driven</i>	 AMI	Merck <i>1-monthly</i>	 TDF/FTC	Gilead <i>Daily</i>		Enema	5P12	5P12-RANTES	
 CAB	CONRAD	 CAB	PATH/ Queens Belfast University		 TFV	Johns Hopkins			 FTC/TAF	Gilead <i>Daily</i>		Intramuscular injection	AcOH	Acetic acid	
 CAB	CONRAD	 DS03	Queen's Belfast University						 CAB	ViiV-GSK <i>2-monthly</i>		Implant	AMI	Alimatravir	
 TFV	Gilead	 CAB	University of North Carolina		BIOEQUIVALENCE					 LEN	Gilead <i>6-monthly</i>		Micro-array patch	AVP	Antiviral peptide
 F/TAF	Houston Methodist	 5P12	Mintaka												
 MAVR	ViiV/ Pfizer	 TAF	RTI		 CAB	ViiV-GSK <i>4-monthly</i>	 LEN	Gilead <i>12-monthly</i>	 DPVR	Pop Council <i>1-monthly</i>				DPVR	Dapivirine
 DPVR	University of Pittsburgh				 DPVR	Pop Council <i>3-monthly</i>	 LEN	Gilead <i>Weekly *</i>						EFDA	Islatravir
Multipurpose Prevention Technologies (MPTs)															
 sAC AVP	Oak Crest	 DPVR PRTV LVGR	University of North Carolina	 DPVR LVGR	Pop Council	 TAF ELVG	CONRAD					Vaginal film	FTC/TAF	Descovy	
 ETGS QGRF ETED	Pop Council/ Oak Crest	 ETGS EFDA ETED	University of North Carolina	 TAF ELVG DOXY	CONRAD	 AcOH N-9	National Research Inst. for Family Planning, China					Vaginal gel	GAA	Glossypol acetate	
 mAb TDF	Oak Crest/ University of North Carolina	 COP LAC	Pop Council/ Queen's University Belfast/ Weill Cornell	 PPCM	Yaso Therapeutics	BIOEQUIVALENCE						Vaginal insert	LAC	Lactide	
 QGRF UN	SwiftPharma	 QGRF ORAC	Pop Council								 F/ TDF ETED LVGR	Viatris*			
 ARV UN	CONRAD	 TFV GAA NTG	Beijing Inst. of Geriatrics/ North Carolina State University									Vaginal ring	LVGR	Levonogestrel	
 CAB MPA	University of North Carolina	 ETGS EFDA LEN	UW, Methodist Hospital Research (HMRI)									Intra-uterine device	mAb	Monoclonal antibody	
 LVGR UN	CONRAD	 DPVR LVGR	Magee-Women's Research Inst. (MWRIF)/ University of Pittsburgh									Vaginal nanofiber	MAVR	Maraviroc	
 PRG UN	MWRIF/ University of Pittsburgh	 mAb	MWRIF/ University of Pittsburgh										MPA	Medroxyprogester-one Acetate	
 LVGR TFV	University of Lagos	 NGMN UN	PATH/ Queens Belfast University										N-9	Nonoxinol	
 COP UN	University of Washington	 TFV NFP	University of Lagos										NFP	Nifedipine	
													NGMN	Norelgestromin	
													NTG	Nitroglycerin	
													ORAC	Organic acids	
													PPCM	Polyphenylene carboxymethylene	
													PRG	Progestin	
													PRTV	Pritelivir	
													QGRF	Q-Griffithsin	
													sAC	Soluble adenylyl cyclase	
													TFV	Tenofovir	
													TAF	Tenofovir Alafenamide	
													TDF	Tenofovir Disoproxil Fumarate	
													TDF/FTC	Truvada	
													UN	Unspecified	
													Zinc	Zinc	

* Submitted and pending regulatory approval



www.avac.org
September 2026

* Submitted and pending regulatory approval